OKYO

OKYO Pharma Limited (OKYO) ESG Analysis Analysis (2026)

Invetso Score: 5.3/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.2 (Moderate)

OKYO’s environmental profile appears broadly neutral versus peers because the provided metrics show no disclosed R&D intensity, limiting evidence of differentiated resource-efficiency practices.

As a clinical-stage biotech, its direct operational footprint is typically lighter than manufacturing-heavy peers, but the absence of disclosed environmental controls prevents a stronger relative score.

No peer-benchmarkable emissions, energy, water, or waste data were provided, so environmental positioning cannot be shown as advantaged versus better-disclosing peers.

Environmental risk is likely more compliance-driven than operationally material, which keeps the profile above weak but below peers with clearer sustainability disclosure and management.

Social

Score:

OKYO’s social positioning is constrained by limited disclosure, because the provided data do not evidence workforce, patient-safety, or community metrics versus peers.

In biotech, clinical and product-safety governance is material, yet no trial-diversity, adverse-event, or access-related disclosures were provided to support a stronger peer ranking.

Stock-based compensation to revenue is shown as zero in the supplied metrics, which avoids signaling outsized dilution-related employee alignment concerns relative to peers.

Overall social performance appears moderate because the company lacks visible controversies in the provided information, but also lacks the transparent programs peers use to differentiate.

Governance

Score:

Governance is held back by sparse disclosure, since the provided metrics do not show board independence, audit quality, or shareholder-rights features versus peers.

The zero debt-to-equity ratio reduces balance-sheet complexity, but it does not substitute for stronger governance evidence on oversight, controls, and capital discipline.

Net debt to EBITDA is reported at 1.59, suggesting manageable leverage, yet peer-relative governance strength depends more on transparency and board effectiveness than leverage alone.

With no disclosed governance controversies in the supplied data, OKYO appears neither clearly advantaged nor structurally impaired, leaving it around the peer median.

Overall Score

Score:

OKYO screens as a moderate ESG performer versus peers because limited disclosure and the absence of differentiating sustainability evidence outweigh the lack of major controversies.

Score Driver: Limited Peer-Benchmarkable ESG Disclosure

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on OKYO Pharma Limited. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →